The euro dropped against the U.S. dollar, while U.S. Treasury yields slipped on Thursday in choppy trading, after the European Central Bank (ECB) said it would continue its bond-buying scheme until at least September 2018 at a reduced pace.
The ECB said it would cut its bond purchases in half to 30 billion euros a month from January, but hedged its bets by extending asset buys by nine months, given the continuously low inflation.
U.S. Treasury yields slipped, in line with the eurozone bond market, after the ECB decision.
“U.S. yields are following global yields lower, fairly sharply as well,” said Gennadiy Goldberg, interest rates strategist at TD Securities in New York.
“The risk of the ECB being a little more hawkish has led to the rise in yields for the last week or so. So this is a little bit of a spillover effect,” Goldberg added.
Benchmark 10-year U.S. Treasury notes last rose 1/32 in price to yield 2.4427 percent, from 2.444 percent late on Wednesday.
The 30-year bond last fell 3/32 in price to yield 2.9591 percent, from 2.955 percent late on Wednesday
Gold dipped as the dollar gained against the euro after the ECB decision to trim bond purchases and as it hedged that move by also extending the lifespan of its bond-buying program.
Spot gold dropped 0.3 percent to USD 1,273.50 an ounce.
The dollar index rose 0.7 percent, with the euro down 0.95 percent to USD 1.17 after the ECB decision spurred sales of the single currency.
MSCI’s gauge of stocks across the globe gained 0.13 percent, with equity markets broadly mixed.
The pan-European FTSEurofirst 300 index rose 0.94 percent, while Japan’s Nikkei rose 0.15 percent.
On Wall Street, the Dow Industrials index rose on gains across sectors, but losses in Celgene held back the two other major indexes in one of the busiest days of third-quarter earnings.
The Dow Jones Industrial Average last rose 117.47 points, or 0.5 percent, to 23,446.93, the S&P 500 gained 8.23 points, or 0.32 percent, to 2,565.38 and the Nasdaq Composite added 14.86 points, or 0.23 percent, to 6,578.76.
Celgene shares dropped 16.0 percent after the biopharmaceutical company reported disappointing sales for its psoriasis treatment drug Otezla.
Oil slipped, pressured by an unexpected increase in U.S. crude inventories, high U.S. production and exports, but stayed near multi-month highs on support from tighter crude markets.
U.S. crude fell 0.02 percent to USD 52.17 per barrel and Brent was last at USD 58.31, down 0.22 percent on the day.